4.03MMarket Cap
LossP/E TTM
Galmed Pharmaceuticals Ltd
Key Figures
0.604Open
0.620High
140.89KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.14%Turnover Ratio
0.599Prev. Close
0.540Low
64.62KTurnover
LossP/E Static
0.26P/B
0.00%Div Yield TTM
-55.53%ROA
2.34052wk High
0.20Volume Ratio
-7.52MNet Profit
6.58MShares
-2.3912EPS TTM
0.68Beta
-64.21%ROE
0.41152wk Low
13.26%Amplitude
--Gross Margin
4.03MMarket Cap
0.85Reward/Risk
5.91%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Galmed Pharmaceuticals Ltd's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 157 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 0.00.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Galmed Pharmaceuticals Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Galmed Pharmaceuticals Ltd Highlights
StrengthsRisks
Galmed Pharmaceuticals Ltd News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Galmed Pharmaceuticals Ltd
GLMD
1
Ionis Pharmaceuticals Inc
IONS
25
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Galmed Pharmaceuticals Ltd Info
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Ticker SymbolGLMD
CompanyGalmed Pharmaceuticals Ltd
CEOBaharaff (Allen)
Websitehttps://www.galmedpharma.com
Shareholders
FAQs
What is the current price of Galmed Pharmaceuticals Ltd (GLMD)?
The current price of Galmed Pharmaceuticals Ltd (GLMD) is 0.61.
What is the symbol of Galmed Pharmaceuticals Ltd?
The ticker symbol of Galmed Pharmaceuticals Ltd is GLMD.
What is the 52-week high of Galmed Pharmaceuticals Ltd?
The 52-week high of Galmed Pharmaceuticals Ltd is 2.34.
What is the 52-week low of Galmed Pharmaceuticals Ltd?
The 52-week low of Galmed Pharmaceuticals Ltd is 0.41.
What is the market capitalization of Galmed Pharmaceuticals Ltd?
The market capitalization of Galmed Pharmaceuticals Ltd is 4.03M.
What is the Earnings Per Share (EPS TTM) of Galmed Pharmaceuticals Ltd (GLMD)?
The Earnings Per Share (EPS TTM) of Galmed Pharmaceuticals Ltd (GLMD) is -2.39.
